Tuppin P, Moysan V, de Peretti C, Schnitzler A, Fery-Lemonnier E, Woimant F
Caisse nationale de l'assurance maladie des travailleurs salariés CNAMTS - direction de la stratégie des études et des statistiques, 26-50, avenue du Professeur-André-Lemierre, 75986 Paris cedex 20, France.
Rev Neurol (Paris). 2013 Feb;169(2):126-35. doi: 10.1016/j.neurol.2012.04.002. Epub 2012 Jun 28.
This study evaluates comorbidities, primary and secondary drug prevention and two years survival among patients hospitalized for stroke during the first half of 2008.
First hospitalization with stroke diagnosis was identified by using the national hospital discharge database and linked to the reimbursement database of the beneficiaries covered by the general health insurance scheme (74% of the 64 million population). A medication was considered to be used when there were more than two reimbursements over the 6 months following or preceding hospitalization.
Among the 36,844 patients with stroke, 31.6% had a main diagnosis of transient ischemic attack (TIA), 53.6% a cerebral infarct (CI) and 14.8% a cerebral hemorrhage (CH). For the 8429 patients aged less than 60 years, high frequency of low-income and full health insurance coverage (11% of the covered population) was found for CI (17.6%) and CH (24.6%). Specific refund for invalidating stroke before hospitalization was found for 16% of patients with CI and 10.5% of those with CH. During the two previous years, around 7% of all patients were hospitalized for stroke, 30% for arterial hypertension, 13% for cardiac electric disorders, 10% for coronary disease and 12% for diabetes. Death rates one month after hospitalization were 11.3% for CI and 33.8% for CH, and two years after 22.5% for CI, 43% for CH and 7.7% for TIA. At least one antihypertensive drug treatment was found for 55.2% of patients with a TIA before hospitalization and 62.9% after and respectively 59.4% and 65.8% for CI and 51.1% and 57.7% for CH. Before hospitalization, beta-blocker was the most frequent antihypertensive class (21 to 25.6% according to stroke type). After hospitalization, frequency increased for angiotensin-converting enzyme inhibitors among CI patients (31% vs. 18.7%) and calcium-channel blockers among CH patients (27.1% vs. 13.7%). Antiplatelet drugs were used by 58% of the patients with CI after hospitalization (27.8% before). An anticoagulant drug was present for 74.8% of patients with CI, 69.5% for TIA and 19.2% for CH. Among patients with ischemic stroke, half of them had a lipid-lowering drug after hospitalization. A combination of antihypertensive, anticoagulant and lipid lowering drugs was found for 32.9% of patients with a TIA, 39.9% for CI and 7.6% for CH after hospitalization.
These patients presented frequently a history of stroke and comorbidities and their level of secondary prevention must be improved.
本研究评估了2008年上半年因中风住院患者的合并症、一级和二级药物预防情况以及两年生存率。
通过国家医院出院数据库确定首次因中风诊断而住院的患者,并将其与一般健康保险计划覆盖的受益人的报销数据库相链接(6400万人口中的74%)。当在住院前后6个月内有超过两次报销时,一种药物被视为被使用。
在36844例中风患者中,31.6%的主要诊断为短暂性脑缺血发作(TIA),53.6%为脑梗死(CI),14.8%为脑出血(CH)。在8429例年龄小于60岁的患者中,CI(17.6%)和CH(24.6%)患者中低收入和全额医保覆盖的频率较高(占参保人群的11%)。16%的CI患者和10.5%的CH患者在住院前有中风致残的特定退款。在前两年中,所有患者中约7%因中风住院,30%因动脉高血压住院,13%因心脏电紊乱住院,10%因冠心病住院,12%因糖尿病住院。住院后1个月的死亡率CI为11.3%,CH为33.8%,两年后CI为22.5%,CH为43%,TIA为7.7%。住院前,55.2%的TIA患者至少接受过一种抗高血压药物治疗,住院后为62.9%;CI患者分别为59.4%和65.8%,CH患者为51.1%和57.7%。住院前,β受体阻滞剂是最常用的抗高血压药物类别(根据中风类型为21%至25.6%)。住院后,CI患者中血管紧张素转换酶抑制剂的使用频率增加(31%对18.7%),CH患者中钙通道阻滞剂的使用频率增加(27.1%对13.7%)。住院后,58%的CI患者使用了抗血小板药物(住院前为27.8%)。74.8%的CI患者、69.5%的TIA患者和19.2%的CH患者使用了抗凝药物。在缺血性中风患者中,一半患者住院后使用了降脂药物。住院后,32.9%的TIA患者、39.9%的CI患者和7.6%的CH患者同时使用了抗高血压、抗凝和降脂药物。
这些患者经常有中风和合并症病史,其二级预防水平必须提高。